NR3C1 and Hyperglycemia: Lastly, we demonstrated that the GR antagonist RU-486, which has previously been shown to diminish HGP and hyperglycemia in diabetic animals [29] can suppress G6PC expression in our cell-based assay in a manner comparable to knocking down that receptor.